Santa Monica, CA, Nov. 14, 2017 (GLOBE NEWSWIRE) — BioSig Technologies(OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has engaged Tiffini Wittwer as Chief Regulatory and Compliance Officer […]
Other News
Bay Area’s Avinger Axes Jobs, Q3 Sales Down 61%
Beleaguered Avinger, Inc. is slashing more jobs. In its latest financial disclosure, Avinger reported a 61 percent decline in sales since the same time last year and would continue its strategic reorganization to save cash. The company said headcount has been reduced to 73 employees as of Oct. 15. That number includes […]
Medtronic gains new CPT codes for Venous device in 2018
Medtronic’s VenaSeal Closure System Receives New CPT Codes By Endovascular Today November 13, 2017—Medtronic has advised that their VenaSeal closure system received a favorable new CPT code as a Level 4 vascular procedure as part of the calendar year 2018 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center […]
Neovasc Inc. to Host Third Quarter 2017 Conference Call
VANCOUVER, Nov. 10, 2017 /PRNewswire/ – Neovasc Inc.(NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call that same day at 4:30 pm Eastern Time hosted by Mr. Alexei […]
Plaxgen Plaque Array Lipid-Modifying Drugs Study Published in Journal of Visualized Experiments
FREMONT, Calif., Nov. 13, 2017 /PRNewswire/ — Plaxgen Inc,developing flow cytometry-based blood diagnostics for plaque-associated diseases, such as atherosclerosis and Alzheimer’s, announced that new research exploring the effect of lipid-lowering drugs, including statins, on the morphology of cholesterol particles in human serum samples was published in the peer-reviewed journal, “Journal of […]
Stryker Announces Publication of the DAWN Trial Results in the New England Journal of Medicine
KALAMAZOO, Michigan, USA, Nov. 13, 2017 /PRNewswire/ — The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from an ischemic stroke receives thrombectomy, […]
Cambridge’s PlaqueTec Names Former Dimension Therapeutics CEO as New Leader
CAMBRIDGE, England, November 13, 2017 /PRNewswire/ — The Board of Directors of PLAQUETEC LTD (‘PlaqueTec’) today announced the appointment of Annalisa Jenkins, MBBS, FRCP, as the company’s Chief Executive Officer. Dr. Jenkins, most recently CEO of U.S.-based Dimension Therapeutics, will lead the 2018 launch of the pioneering biomarker-based PlaqueTec Liquid Biopsy System(TM) […]
IP veteran Andrew Filler joins BioSig Technologies’ Board of Directors
Santa Monica, CA, Nov. 10, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced the appointment of Andrew Filler to the Company’s Board of Directors. […]
Siemens to Replace Healthineers CFO in Preparation for Listing
FRANKFURT – Siemens AG has replaced the chief financial officer of its Healthineers unit as it prepares to go public next year. This morning, Siemens announced that Jochen Schmitz, currently the head of accounting for the Siemens Group, will replace Thomas Rathmann on Dec. 1. Rathmann is leaving the Healthineers unit by mutual agreement, the company announced. Siemens praised […]
Neovasc Announces $65M Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants
VANCOUVER, Nov. 9, 2017 /PRNewswire/ – Neovasc (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 Series A units (the “Series A Units”) of Neovasc and 19,066,780 Series B units (the “Series B Units” and together with the Series A Units, the “Units”) of the Company, at a […]



